



Media Release

12 December 2011

Ondek's Chief Scientist presents Phase 1 results at European Vaccine Conference in Brussels, Belgium.

Ondek's Chief Scientist, Dr. Mohammed Benghezal attended and presented Phase 1 Safety and immunogenicity data of specifically chosen *H.pylori* strains at Europe's leading vaccine conference. Selected *H.pylori* strains are used in the *Helicobacter Pylori Platform Technology* (HPPT), which is an oral delivery platform for vaccines. Preclinical and clinical data on recipient *H.pylori* strains was presented, with a focus on safety outcomes from a randomised, double-blind, placebo controlled Phase 1 challenge study in healthy volunteers.

The meeting is Europe's leading vaccine conference, which was held in Brussels, Belgium. The conference covered the latest technological advances in vaccine delivery platforms, vectors, adjuvants and production strategies for the new vaccine targets. Vaccine companies of all sizes attended the conference, such as: GlaxoSmithKline; Pfizer; Crucell; Novartis Vaccines; Sanofi Aventis; Takeda; MedImmune and many others.

About Ondek

Ondek Pty Ltd is an Australian biotechnology company developing a novel vaccine and drug delivery platform, based on its patented "Helicobacter pylori Platform Technology" (HPPT). The platform utilises the unique characteristics of a genetically modified *Helicobacter pylori* bacterium to deliver a diverse range of therapeutics to the patient, including vaccines or other biologicals. Ondek was founded by Professor Barry Marshall, a world authority and co-discoverer of the *Helicobacter pylori* organism and co-recipient of the 2005 Nobel Prize for Medicine and Physiology. www.ondек.com

Contact: Peter Hammond +61 2 9332 0600.